BR112024001927A2 - Formas de dosagem gastrorretentivas de 5-hidroxitriptofano - Google Patents
Formas de dosagem gastrorretentivas de 5-hidroxitriptofanoInfo
- Publication number
- BR112024001927A2 BR112024001927A2 BR112024001927A BR112024001927A BR112024001927A2 BR 112024001927 A2 BR112024001927 A2 BR 112024001927A2 BR 112024001927 A BR112024001927 A BR 112024001927A BR 112024001927 A BR112024001927 A BR 112024001927A BR 112024001927 A2 BR112024001927 A2 BR 112024001927A2
- Authority
- BR
- Brazil
- Prior art keywords
- htp
- carbidopa
- dosage forms
- release
- gastroretentive dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163227915P | 2021-07-30 | 2021-07-30 | |
| PCT/US2022/038914 WO2023009841A1 (en) | 2021-07-30 | 2022-07-29 | 5-hydroxytryptophan gastroretentive dosage forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112024001927A2 true BR112024001927A2 (pt) | 2024-04-30 |
Family
ID=83049744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112024001927A BR112024001927A2 (pt) | 2021-07-30 | 2022-07-29 | Formas de dosagem gastrorretentivas de 5-hidroxitriptofano |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11752107B2 (https=) |
| EP (1) | EP4362919A1 (https=) |
| JP (1) | JP2024528125A (https=) |
| KR (1) | KR20240039030A (https=) |
| CN (1) | CN116801868A (https=) |
| AU (1) | AU2022320730A1 (https=) |
| BR (1) | BR112024001927A2 (https=) |
| CA (1) | CA3226223A1 (https=) |
| CL (1) | CL2024000271A1 (https=) |
| CO (1) | CO2024002256A2 (https=) |
| IL (1) | IL310523A (https=) |
| MX (1) | MX2024001390A (https=) |
| WO (1) | WO2023009841A1 (https=) |
| ZA (1) | ZA202401725B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12409163B2 (en) | 2021-07-30 | 2025-09-09 | Evecxia Therapeutics, Inc. | Method of enhancing 5-hydroxytryptophan (5-HTP) exposure |
| US11779567B2 (en) | 2021-10-14 | 2023-10-10 | Evecxia Therapeutics, Inc. | Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes |
| WO2024148354A1 (en) * | 2023-01-06 | 2024-07-11 | Evecxia Therapeutics, Inc. | A method of enhancing 5-hydroxytryptophan (5-htp) exposure |
| WO2025042927A2 (en) * | 2023-08-24 | 2025-02-27 | Merck Sharp & Dohme Llc | Sustained-release formulations for poorly permeable cyclic peptides |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4140755A (en) | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
| US4191184A (en) | 1977-01-06 | 1980-03-04 | Carlisle Jeffrey A | Intravenous infusion regulation system with reciprocal metering means |
| US4658038A (en) | 1982-10-07 | 1987-04-14 | Research Foundation For Mental Hygiene, Inc. | N-acylated 5-hydroxytryptophan amide derivatives |
| IL87710A (en) | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
| FR2654931B1 (fr) * | 1989-11-24 | 1993-08-27 | Trouillas Paul | Compositions pharmaceutiques possedant une activite sur l'ataxie et les troubles de l'equilibre, cerebelleux ou autres, de toutes origines, comprenant l'association de l-5-hydroxytryptophane et de carbidopa. |
| IT1282650B1 (it) * | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
| CA2290624C (en) | 1997-06-06 | 2006-12-05 | John W. Shell | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| IN186245B (https=) | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
| EP1063973B1 (en) | 1998-03-19 | 2016-11-16 | Bristol-Myers Squibb Company | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
| US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| US7674480B2 (en) | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US20060013875A1 (en) | 2002-05-29 | 2006-01-19 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| US7094427B2 (en) | 2002-05-29 | 2006-08-22 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| BR0314804A (pt) * | 2002-09-28 | 2005-08-02 | Mcneil Ppc Inc | Forma de dosagem de liberação modificada |
| EP1542662A1 (en) | 2002-09-28 | 2005-06-22 | McNEIL-PPC, INC. | Immediate release dosage form comprising shell having openings therein |
| AU2003293423A1 (en) | 2002-12-06 | 2004-06-30 | Xenoport, Inc. | Carbidopa prodrugs and uses thereof |
| ITMI20041689A1 (it) | 2004-09-01 | 2004-12-02 | Bojidar Mihaylov Stankov | Nuove formulazioni di rilascio controllato contenenti 5-idrossitriptofano e triptofano |
| US20080268045A1 (en) | 2006-11-09 | 2008-10-30 | Proprius Pharmaceuticals, Inc. | Sustained release methotrexate formulations and methods of use thereof |
| KR20080076382A (ko) | 2007-02-15 | 2008-08-20 | (주)아모레퍼시픽 | 실로스타졸의 제어방출 제제 및 그 제조방법 |
| EP1980743B1 (en) | 2007-04-10 | 2015-09-09 | Nissan Motor Co., Ltd. | Fuel pump driving device |
| US8969400B2 (en) | 2007-10-01 | 2015-03-03 | Duke University | Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound |
| KR101601649B1 (ko) | 2008-04-18 | 2016-03-09 | 인텍 파마 리미티드 | 카르비도파／레보도파 위체류 약물 전달 |
| ZA200903854B (en) | 2008-06-19 | 2011-02-23 | Univ Of The Witwatesrand Johannesburg | A gastroretentive pharmaceutical dosage form |
| JP2012500221A (ja) | 2008-08-15 | 2012-01-05 | ディポメド，インコーポレイティド | Ｃｎｓ障害の処理及び予防のための胃保持性医薬組成物 |
| WO2011146611A1 (en) | 2010-05-18 | 2011-11-24 | Abon Pharmaceuticals, Llc | Modified gastroretentive drug delivery system for amine drugs |
| US20130078290A1 (en) * | 2010-06-01 | 2013-03-28 | Rubicon Research Private Limited | Gastroretentive Dosage Forms Of GABA Analogs |
| EP2629615B1 (en) | 2010-10-22 | 2018-10-10 | Duke University | Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies |
| CN103554005A (zh) | 2013-11-22 | 2014-02-05 | 长沙理工大学 | 一种左旋5-羟基色氨酸的简便合成新方法 |
| US20170266112A1 (en) | 2014-06-11 | 2017-09-21 | Massachusetts Institute Of Technology | Residence structures and related methods |
| HK1258050A1 (zh) | 2015-10-23 | 2019-11-01 | Lyndra Therapeutics, Inc. | 用於治疗剂缓释的胃驻留系统及其使用方法 |
| BR112020015068A2 (pt) | 2018-01-29 | 2021-01-05 | Duke University | Composições e métodos de melhoramento de biodisponibilidade de 5-hidroxitriptofano |
| CN112469400A (zh) * | 2018-06-19 | 2021-03-09 | 新加坡国立大学 | 对于各种适应症的生物利用度更佳的5-羟色氨酸(5-htp)制剂 |
| EP3820468A4 (en) * | 2018-07-11 | 2022-03-23 | Duke University | Use of sustained-release 5-hydroxytryptophan in treating gastrointestinal disorders |
-
2022
- 2022-07-29 WO PCT/US2022/038914 patent/WO2023009841A1/en not_active Ceased
- 2022-07-29 IL IL310523A patent/IL310523A/en unknown
- 2022-07-29 MX MX2024001390A patent/MX2024001390A/es unknown
- 2022-07-29 CA CA3226223A patent/CA3226223A1/en active Pending
- 2022-07-29 AU AU2022320730A patent/AU2022320730A1/en active Pending
- 2022-07-29 EP EP22758331.7A patent/EP4362919A1/en active Pending
- 2022-07-29 JP JP2024505541A patent/JP2024528125A/ja active Pending
- 2022-07-29 KR KR1020247006922A patent/KR20240039030A/ko active Pending
- 2022-07-29 CN CN202280011205.2A patent/CN116801868A/zh active Pending
- 2022-07-29 BR BR112024001927A patent/BR112024001927A2/pt unknown
- 2022-07-29 US US17/877,699 patent/US11752107B2/en active Active
-
2023
- 2023-09-11 US US18/244,424 patent/US20240108582A1/en not_active Abandoned
-
2024
- 2024-01-29 CL CL2024000271A patent/CL2024000271A1/es unknown
- 2024-02-26 CO CONC2024/0002256A patent/CO2024002256A2/es unknown
- 2024-02-28 ZA ZA2024/01725A patent/ZA202401725B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024528125A (ja) | 2024-07-26 |
| IL310523A (en) | 2024-03-01 |
| WO2023009841A1 (en) | 2023-02-02 |
| KR20240039030A (ko) | 2024-03-26 |
| CA3226223A1 (en) | 2023-02-02 |
| US11752107B2 (en) | 2023-09-12 |
| CL2024000271A1 (es) | 2024-08-16 |
| US20230047338A1 (en) | 2023-02-16 |
| US20240108582A1 (en) | 2024-04-04 |
| EP4362919A1 (en) | 2024-05-08 |
| CO2024002256A2 (es) | 2024-03-18 |
| CN116801868A (zh) | 2023-09-22 |
| ZA202401725B (en) | 2025-08-27 |
| AU2022320730A1 (en) | 2024-03-14 |
| MX2024001390A (es) | 2024-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112024001927A2 (pt) | Formas de dosagem gastrorretentivas de 5-hidroxitriptofano | |
| CO2022011728A2 (es) | Composiciones y usos de glp-1 | |
| AR077199A1 (es) | Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia | |
| PE20211588A1 (es) | Compuestos y sus usos para aliviar sintomas asociados a la menopausia | |
| BR112022026699A2 (pt) | Mecanismo de liberação de fragrâncias, método e usos do mesmo | |
| PE20080400A1 (es) | Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas | |
| MX2024010155A (es) | Formulacion combinada de cedazuridina | |
| CO6280488A2 (es) | Combinacion farmaceutica | |
| CL2012003119A1 (es) | Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre. | |
| AR083095A1 (es) | Cocristal de aprepitant l-prolina y composicion farmaceutica | |
| ECSP099734A (es) | Composición farmaceutica que comprende la combinación de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante | |
| CO2025008948A2 (es) | Composición farmacéutica que comprende enavogliflozina y metformina | |
| BRPI0700133A (pt) | composição farmacêutica compreendendo tramadol e cetoprofeno em combinação | |
| ECSP16005208A (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación | |
| CL2021002430A1 (es) | Formulación de tableta vaginal | |
| MX2022005388A (es) | Compuestos de pirrolidina y piperidina. | |
| AR114006A1 (es) | Combinación farmacéutica en la forma de comprimidos en bicapa que comprende ketorolaco trometamina y tramadol clorhidrato, y su uso para el tratamiento del dolor | |
| CO2022014548A2 (es) | Forma de dosificación oral sólida que comprende pomalidomida | |
| BR112016006485A2 (pt) | composições de liberação pulsátil revestidas por compressão | |
| BR112022020755A2 (pt) | Uso de uma composição farmacêutica | |
| BR112018017167A2 (pt) | titulação de cebranopadol | |
| GT200700005A (es) | Composicion farmaceutica estable de carisoprodol y meloxicam | |
| AR121363A1 (es) | Composiciones y usos de glp-1 | |
| BR112023017672A2 (pt) | Película delgada oral | |
| AR131156A1 (es) | Composiciones de silodosina de liberación modificada y uso de las mismas en métodos para anticoncepción masculina |